DDInter1042 DDInter1077
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.
Liraglutide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Liraglutide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Liraglutide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esterified estrogens
Liraglutide {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Liraglutide may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Liraglutide may lead to a major life threatening interaction when taken with Bexarotene